Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-label, Non-comparative, International, Multicentre Study to Assess the Efficacy and Safety of KU 0059436 Given Orally Twice Daily in Patients With Advanced BRCA1 or BRCA2 Associated Ovarian Cancer

NCT00494442 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00494442
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00494442 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-label, Non-comparative, International, Multicentre Study to Assess the Efficacy and Safety of KU 0059436 Given Orally Twice Daily in Patients With Advanced BRCA1 or BRCA2 Associated Ovarian Cancer
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
June 11, 2007
Completion date
July 20, 2017
Enrollment
58 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian neoplasm